| Name | Puromycin aminonucleoside |
| Description | Puromycin aminonucleoside (NSC 3056) is an aminonucleoside antibiotic and a purine analog of puromycin. It can reversibly inhibit dipeptidyl peptidase and cytosolic alanine aminopeptidase, increase podocyte permeability by regulating ZO-1 in an oxidative stress-dependent manner, induce apoptosis, and promote the secretion of migrasomes. It is commonly used to induce nephrotic syndrome models in research. |
| In vitro | Puromycin aminonucleoside -induced podocyte apoptosis is p53 dependent. Puromycin aminonucleoside causes podocyte apoptosis in a time-dependent manner. The IC50 values for PMAT-expressing and vector-transfected cells are 48.9 and 122.1 μM, respectively, suggesting expression of PMAT-enhanced cell sensitivity to Puromycin aminonucleoside. Puromycin aminonucleoside uptake in PMAT-expressing cells is fourfold higher at pH 6.6 than that at pH 7.4. Puromycin aminonucleoside (30 μg/mL) markedly enhances p53 protein levels in podocytes. Puromycin aminonucleoside (250 μM) is toxic to both PMAT-expressing and vector-transfected cells [2][4]. |
| In vivo | Rats administered Puromycin aminonucleoside (100 mg/kg, s.c.) exhibited reduced weight gain and elevated serum creatinine levels compared to controls. The podocyte count per glomerulus in control rats stood at 95.5±17.6, dropping to 90.7 by Day 4 in rats with Puromycin aminonucleoside (8 mg/100 g, i.v.)-induced nephrosis. Furthermore, nephrin levels per glomerulus in controls were 1.02±0.11 fmol, which decreased significantly in nephrosis rats to 0.46±0.06 fmol and 0.35±0.04 fmol on Days 4 and 7, respectively. This reduction in nephrin per podocyte was closely linked to proteinuria development in rats affected by Puromycin aminonucleoside nephrosis [5][6]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 50 mg/mL (169.89 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.8 mM), Sonication is recommended.
DMSO : 33 mg/mL (112.13 mM), Sonication is recommended.
|
| Keywords | Puromycin aminonucleoside | NSC-3056 | NSC3056 | Inhibitor | inhibit | DPP | dipeptidyl peptidase II | Dipeptidyl Peptidase | Bacterial | Apoptosis | antibiotic | Aminopeptidase |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Formamide | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | ReFRAME Related Library | Hematonosis Compound Library | Antibiotics Library | Inhibitor Library | NO PAINS Compound Library | Anti-Bacterial Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
United States
